Acorn Financial Advisory Services Inc. ADV Takes $743,000 Position in Organon & Co. (NYSE:OGN)

Acorn Financial Advisory Services Inc. ADV purchased a new position in Organon & Co. (NYSE:OGN - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 38,833 shares of the company's stock, valued at approximately $743,000.

A number of other large investors also recently added to or reduced their stakes in OGN. Versant Capital Management Inc boosted its stake in shares of Organon & Co. by 200.2% in the second quarter. Versant Capital Management Inc now owns 1,207 shares of the company's stock worth $25,000 after acquiring an additional 805 shares during the last quarter. William B. Walkup & Associates Inc. purchased a new position in Organon & Co. in the 2nd quarter valued at $31,000. Abich Financial Wealth Management LLC boosted its stake in Organon & Co. by 5,646.3% during the 3rd quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company's stock worth $45,000 after purchasing an additional 2,315 shares during the last quarter. Atlas Capital Advisors LLC grew its holdings in shares of Organon & Co. by 2,236.5% during the second quarter. Atlas Capital Advisors LLC now owns 2,243 shares of the company's stock worth $46,000 after buying an additional 2,147 shares in the last quarter. Finally, Trust Co. of Vermont raised its position in shares of Organon & Co. by 109.4% in the third quarter. Trust Co. of Vermont now owns 2,626 shares of the company's stock valued at $50,000 after buying an additional 1,372 shares during the last quarter. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently issued reports on OGN. JPMorgan Chase & Co. cut shares of Organon & Co. from a "neutral" rating to an "underweight" rating and upped their price objective for the company from $18.00 to $20.00 in a research note on Friday, September 6th. Evercore ISI upgraded Organon & Co. to a "strong-buy" rating in a report on Wednesday, September 18th.

Organon & Co. Trading Down 0.5 %

Shares of NYSE OGN traded down $0.08 during trading on Friday, hitting $16.04. 2,570,213 shares of the company were exchanged, compared to its average volume of 2,735,779. The company has a fifty day moving average price of $18.76 and a 200-day moving average price of $20.04. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.17 and a current ratio of 1.70. The firm has a market capitalization of $4.13 billion, a PE ratio of 3.18, a P/E/G ratio of 0.73 and a beta of 0.84. Organon & Co. has a 12-month low of $10.84 and a 12-month high of $23.10.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its earnings results on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing analysts' consensus estimates of $0.90 by ($0.03). The firm had revenue of $1.58 billion for the quarter, compared to analysts' expectations of $1.56 billion. Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. Organon & Co.'s revenue for the quarter was up 4.1% on a year-over-year basis. During the same period last year, the firm earned $0.78 earnings per share. As a group, equities research analysts expect that Organon & Co. will post 3.97 EPS for the current year.

Organon & Co. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Investors of record on Tuesday, November 12th will be issued a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a yield of 6.98%. The ex-dividend date is Tuesday, November 12th. Organon & Co.'s dividend payout ratio is presently 22.22%.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.